Chan Basho
CFO & COO at Astrana Health
Looking at the balance sheet, we closed the quarter with $260,900,000 in cash and short term investments. As we look ahead to closing the Prospect acquisition this summer, our expected pro form a net leverage will be approximately 3.4 times with the goal of delevering below three times within twelve months post close. For the quarter, we generated $13,600,000 in free cash flow, which included a non recurring debt issuance cost of $5,000,000 related to the recent amendment of our credit agreement with Truist. Excluding this one time financing cost, free cash flow was $18,600,000 representing 51% of adjusted EBITDA for the quarter. We remain confident in our ability to deliver within our previously stated full year guidance for revenue of 2,500,000,000.0 to $2,700,000,000 and adjusted EBITDA of 170,000,000 to $190,000,000 For second quarter twenty twenty five, we expect to generate between $615,000,000 to $665,000,000 of revenue with adjusted EBITDA ranging between $45,000,000 to $50,000,000 Finally, we want to reiterate our previously stated medium term adjusted EBITDA guidance of at least $350,000,000 in 2027.